← Russell 3000 cross-section

TWST Twist Bioscience Corp

Trailing twelve months to 2026-06-30 · as filed 2026-08-03, not restated
Healthcare

Scale

Market cap
$9.6bn
Revenue TTM
$432m
Net income TTM
$-137m
Free cash flow
$-93m
Composite score
40.9
Sector rank
#735

Valuation

P / E
EV / EBITDA
EV / sales
21.9
FCF yield
-0.97%
Earnings yield vs 10-yr
-6.15pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-31.7%
EBITDA margin
-27.7%
ROE
-30.7%
ROIC
-52.0%
Revenue growth
19.2%

Insider activity, last 90 days

Net open-market
$-49.95m
Buyers
0
Sellers
9

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Financial highlights compared to the same periods in the prior fiscal year: • For the three and nine months ended June 30, 2026, revenues increased 23.2% to $118.4 million and 20% to $332.8 million, respectively, driven by strong performance in DNA synthesis and protein solutions and NGS applications. • For the three months ended June 30, 2026, gross margin decreased to 52.8% from 53.4% for the same period in the prior year primarily due to customer mix . Revenues increased 23% to $118.4 million for the three months ended June 30, 2026, as compared to $96.1 million for the three months ended June 30, 2025. …Twist Bioscience Corp, 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →